Top Markets
#1 Zora Zora +32.72%
#2 SAFEcoin SAFEcoin +24.00%
#3 0G 0G +21.53%
#4 Full Moon Full Moon +18.68%
#5 Merlin's Seal BTC Merlin's Seal BTC +16.67%
#6 Axelar Axelar +16.33%
#7 VVS Finance VVS Finance +15.88%
#8 SkyAI SkyAI +14.30%
#9 Cysic Cysic +14.24%
#10 Apertum Apertum +14.01%
Coin of the day
Zora Zora
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Classificação em ações #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Preço da ação
$22.26
Última sincronização: 2024-03-22
Valor de mercado
$553.40M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Graphite Bio, Inc. (GRPH)

Categoria

Healthcare
Lucros da Graphite Bio, Inc. (GRPH)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Graphite Bio, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Graphite Bio, Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH